
    
      A pivotal, single-dose, randomized, open-label, partial replicate, three-period,
      three-sequence, two-treatment, three-way crossover, comparative bioavailability study.

      Ninety-nine, male and female volunteers, 20-45 years of age, with a body mass index (BMI)
      within 18.5-30.0 kg/m2, inclusive, will be enrolled. (The body weight should be over 50 kg,
      inclusive, respectively)

      A single dose of 8 puffs (eq. to budesonide 1280 μg /formoterol fumarate dihydrate 36 μg) in
      each study period.
    
  